Skip to main content

Table 2 Associations between parameters and high dolutegravir (DTG) plasma trough concentrations (≥ 1.06 μg/mL)

From: Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1

  Univariate results Multivariate results
OR 95% CI p-value OR 95% CI p-value
Age ≥ 40 years 0.35 0.15–0.82 0.0144 0.35 0.13–0.92 0.0324
Body weight < 65 kg 0.71 0.33–1.53 0.3864 1.02 0.41–2.57 0.9705
Sex (Male) 3.95 0.90–27.5 0.0693 3.84 0.73–30.5 0.1175
HIV-1-RNA level at the time of sampling (< 50 copies/mL) 0.98 0.04–25.2 0.9894 0.53 0.02–15.7 0.6786
Number of UGT1A1*6 alleles
 0 1    1   
 1 2.52 1.02–6.46 0.0434 3.33 1.24–9.51 0.0164
 2 4.4 × 107 5.21-∞ 0.0003 5.9 × 107 6.90-∞ 0.0001
Number of UGT1A1*28 alleles
 0 1    1   
 1 2.03 0.78–5.57 0.1476 3.61 1.24–11.5 0.0184
 2 2.32 0.21–50.9 0.4862 4.01 0.33–93.4 0.2669
  1. OR odds ratio, CI confidence interval, UGT1A1 uridine diphosphate-glucuronosyltransferase 1A1, HIV human immunodeficiency virus